Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antibody drug conjugate

Bayer symbol

Bayer signs $520m cancer alliance with Seattle Genetics

Will focus on development of antibody-drug conjugates

National Institute for Health and Care Excellence NICE logo

UK backs use of drugs to prevent breast cancer

Daily use of tamoxifen or raloxifene recommended in at-risk women

- PMLiVE

Astellas wins EU approval for prostate cancer drug Xtandi

Will compete with J&J’s big-selling Zytiga

- PMLiVE

Cost deters NICE from Sanofi’s bowel cancer drug Zaltrap

Fails to win recommendation despite patient access scheme

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

- PMLiVE

AbbVie: UK patients want better arthritis care

Study from Humira manufacturer concludes that UK doctors need better collaboration with patients

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

Men’s oesophageal cancer risk “triple that of women”

New data from Cancer Research UK shines slight on 'quiet epidemic'

- PMLiVE

Elotuzumab on track for multiple myeloma

BMS and AbbVie present phase II results at European Haematology Association meeting

- PMLiVE

BMS’ Orencia matches Humira in arthritis study

Data should help drug establish itself against AbbVie's market-leading RA medicine

- PMLiVE

FDA turns down tivozanib for kidney cancer

Agency describes data provided by Aveo Oncology and Astellas as "uninterpretable"

- PMLiVE

­Pfizer signs $635m deal with CytomX for cancer ADCs

Will use biotech's Probody technology to develop antibody-drug conjugates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links